Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study

CONCLUSION: Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.PMID:38538968 | DOI:10.1007/s12094-024-03440-5

Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alejandro Falc ón González Josefina Cruz Jurado Elisenda Llabr és Valenti Roc ío Urbano Cubero Maria Carmen Álamo de la Gala Mar ía Antonia Martínez Guisado Roc ío Álvarez Ambite Carlos Jos é Rodríguez González Marta Am érigo Góngora Lourdes Source Type: research